Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Single-Cell Multiomics Analysis Reveals Potential Drivers of Response to the Anti-TIM3 Inhibitor Sabatolimab Combined with Azacitidine in MDS and CMML

Aonkon Dey, Rupa Narayan, Neal Smith, Alice Tirard, Benjamin Arnold, John McGuire, Thomas Chan, Jennifer Lombardi Story, Timothy Casson, Tanya Toni Behnan, Amir T. Fathi, Gabriela S. Hobbs, Hanno Hock, Philip C. Amrein, Patrick Reeves, Timothy Aaron Graubert, Andrew M. Brunner, Alexandra-Chloé Villani

Blood (2023) 142 (Supplement 1): 4319.

https://doi.org/10.1182/blood-2023-189858

Published: 2023

Journal Articles

Phase I Study of Ixazomib with Conventional Chemotherapy in the Treatment of Acute Myeloid Leukemia in Older Adults

Blood (2022) 140 (Supplement 1): 3309–3311.

https://doi.org/10.1182/blood-2022-160100

Published: 2022

Journal Articles

Emergence of Chronic Myeloid Leukemia in Patients with Myeloproliferative Neoplasms: A Single-Institution Experience

Kevin C. Miller, Jennifer Lombardi Story, Julia Foster, Jenna A. Moran, Amir T. Fathi, Gabriela S. Hobbs

Blood (2022) 140 (Supplement 1): 12295–12296.

https://doi.org/10.1182/blood-2022-170986

Published: 2022

Journal Articles

Outcomes of Therapy with Venetoclax Combined with Hypomethylating Agents in Favorable-Risk Acute Myeloid Leukemia (AML)

Shukaib Arslan, MD, Jianying Zhang, Prajwal Dhakal, MBBS, Jenna A. Moran, NP, Nuthana Naidoo, Jennifer Lombardi Story, Vinod A. Pullarkat, MD, Anthony S. Stein, MD, Guido Marcucci, MD, George Yaghmour, MD, Vijaya R. Bhatt, MD, Amir T. Fathi, Ibrahim Aldoss, MD

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-142780

Published: 2020

Journal Articles

Evaluation of a Pan-Lysyl Oxidase Inhibitor, Pxs-5505, in Myelofibrosis: A Phase I, Randomized, Placebo Controlled Double Blind Study in Healthy Adults

Joan How, MD, Yiwen Liu, Jennifer Lombardi Story, Donna S. Neuberg, ScD, Katya Ravid, PhD DSc, Wolfgang Jarolimek, Brett Charlton, Gabriela S. Hobbs, MD

Blood (2020) 136 (Supplement 1): 16.

https://doi.org/10.1182/blood-2020-139223

Published: 2020

Journal Articles

Phase I Study of Ixazomib Added to Chemotherapy in the Treatment of Acute Lymphoblastic Leukemia in Older Adults

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-139661

Published: 2020

Journal Articles

Phase I Study of Ixazomib with Conventional Chemotherapy in the Treatment of Acute Myeloid Leukemia in Older Adults

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-140584

Published: 2020

Journal Articles

A Phase 1 Trial of Regorafenib in Advanced Myeloid Malignancies

Chi-Joan How, MD, Siyang Ren, Jennifer Lombardi Story, Meghan Bergeron, NP, Julia E. Foster, NP, Philip C. Amrein, MD, Andrew M. Brunner, Amir T. Fathi, Hanno R. Hock, MD PhD, Jenna A. Moran, NP, Rupa Narayan, Donna S. Neuberg, ScD, Aura Y. Ramos, RN, Tina T. Som, RN, Megan Vartanian, RN, Yi-Bin Chen, MD, Gabriela S. Hobbs, MD

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-140278

Published: 2020

Journal Articles

Pregnancy Outcomes, Risk Factors, and Gestational Cell Count Trends in Pregnant Women with Essential Thrombocythemia and Polycythemia Vera

Chi-Joan How, MD, Orly Leiva, BS, Thomas Bogue, BS, Geoffrey Fell, MS, Mark Bustoros, MD, Nathan T. Connell, MD MPH, Jean M. Connors, MD, Irene M. Ghobrial, MD, Nancy Higgins, Nicholas A Jessop, David J. Kuter, Jennifer Lombardi Story, Ann Mullally, MD, Valentina Nardi, MD, Donna S Neuberg, ScD, Rachel Styles, BS, Jeffrey I. Zwicker, MD, Gabriela S. Hobbs, MD, Annemarie E Fogerty, MD

Blood (2019) 134 (Supplement_1): 4172.

https://doi.org/10.1182/blood-2019-127058

Published: 2019

Journal Articles

Phase I Study of Ixazomib in Addition to Chemotherapy for the Treatment of Acute Myeloid Leukemia in Older Adults

Blood (2018) 132 (Supplement 1): 4059.

https://doi.org/10.1182/blood-2018-99-117566

Published: 2018

Journal Articles

Single-Cell RNA-Seq Reveals AML Cellular Hierarchies Relevant to Clinical Outcomes and Immunity

Peter Van Galen, PhD, Volker Hovestadt, PhD, Marc Wadsworth II, Travis Hughes, Gabriel Kenneth Griffin, MD, Julia A. Verga, Jason Stephansky, Timothy J. Pastika, Jennifer Lombardi Story, Geraldine S. Pinkus, MD, Olga Pozdnyakova, MD PhD, Ilene Galinsky, Richard M. Stone, MD, Timothy A. Graubert, MD, Alex K. Shalek, PhD, Jon C. Aster, MD PhD, Andrew A. Lane, MD PhD, Bradley E. Bernstein, MD PhD

Blood (2018) 132 (Supplement 1): 542.

https://doi.org/10.1182/blood-2018-99-113502

Published: 2018

Journal Articles

Phase II Clinical Trial of Alisertib, an Aurora a Kinase Inhibitor, in Combination with Induction Chemotherapy in High-Risk, Untreated Patients with Acute Myeloid Leukemia

Blood (2018) 132 (Supplement 1): 766.

https://doi.org/10.1182/blood-2018-99-115145

Published: 2018

Journal Articles

Phase I Study of Ixazomib in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults

Blood (2018) 132 (Supplement 1): 2704.

https://doi.org/10.1182/blood-2018-99-117506

Published: 2018

Journal Articles

Phase I Study of the Antibody-Drug Conjugate Brentuximab Vedotin Combined with Re-Induction Chemotherapy in Patients with CD30-Expressing Relapsed/Refractory Acute Myeloid Leukemia

Blood (2018) 132 (Supplement 1): 1431.

https://doi.org/10.1182/blood-2018-99-115031

Published: 2018

NARROW

Single-Cell Multiomics Analysis Reveals Potential Drivers of Response to the Anti-TIM3 Inhibitor Sabatolimab Combined with Azacitidine in MDS and CMML

Phase I Study of Ixazomib with Conventional Chemotherapy in the Treatment of Acute Myeloid Leukemia in Older Adults

Emergence of Chronic Myeloid Leukemia in Patients with Myeloproliferative Neoplasms: A Single-Institution Experience

Outcomes of Therapy with Venetoclax Combined with Hypomethylating Agents in Favorable-Risk Acute Myeloid Leukemia (AML)

Evaluation of a Pan-Lysyl Oxidase Inhibitor, Pxs-5505, in Myelofibrosis: A Phase I, Randomized, Placebo Controlled Double Blind Study in Healthy Adults

Phase I Study of Ixazomib Added to Chemotherapy in the Treatment of Acute Lymphoblastic Leukemia in Older Adults

Phase I Study of Ixazomib with Conventional Chemotherapy in the Treatment of Acute Myeloid Leukemia in Older Adults

A Phase 1 Trial of Regorafenib in Advanced Myeloid Malignancies

Pregnancy Outcomes, Risk Factors, and Gestational Cell Count Trends in Pregnant Women with Essential Thrombocythemia and Polycythemia Vera

Phase I Study of Ixazomib in Addition to Chemotherapy for the Treatment of Acute Myeloid Leukemia in Older Adults

Single-Cell RNA-Seq Reveals AML Cellular Hierarchies Relevant to Clinical Outcomes and Immunity

Phase II Clinical Trial of Alisertib, an Aurora a Kinase Inhibitor, in Combination with Induction Chemotherapy in High-Risk, Untreated Patients with Acute Myeloid Leukemia

Phase I Study of Ixazomib in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults

Phase I Study of the Antibody-Drug Conjugate Brentuximab Vedotin Combined with Re-Induction Chemotherapy in Patients with CD30-Expressing Relapsed/Refractory Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only